Congress Pushes Liver Cancer Awareness as Liquid Biopsies Target Screening Gap

IRVINE, Calif. – October 06, 2026 — The intersection of public health policy and diagnostic innovation is coming into sharp focus on Capitol Hill, where a new legislative push aims to address one of America's most lethal and overlooked health crises. Representative Don Bacon (R-NE) has introduced House Resolution 1320, a measure seeking to designate October 15, 2026, as National Liver Cancer Awareness Day.

The resolution, which spotlights the urgent need for early detection, risk identification, and routine surveillance, arrives as the American Cancer Society projects roughly 42,340 new cases of liver and intrahepatic bile duct cancer in the United States this year, alongside nearly 31,000 deaths. Behind the legislative effort is a strategic alignment with the medical technology sector. Helio Genomics, a California-based cancer diagnostics company developing artificial intelligence-powered blood tests, provided input on the resolution, highlighting a growing trend where commercial healthcare innovators actively shape national awareness campaigns to drive clinical adoption.

The Tripling Epidemic and a Broken Surveillance System

The push for national recognition is driven by grim epidemiological data. Over the past four decades, liver cancer incidence in the United States has roughly tripled. The disease disproportionately impacts men, who account for about two-thirds of new cases, and heavily burdens Hispanic, American Indian, Alaska Native, Asian American, and Black communities.

The crisis is compounded by a profound failure in clinical surveillance. While patients with cirrhosis are at high risk for developing hepatocellular carcinoma (HCC) and are advised by clinical guidelines to undergo biannual ultrasound monitoring, adherence is staggeringly low. A comprehensive nationwide study of over 80,000 cirrhosis patients revealed that only about 9 percent completed the recommended ultrasound surveillance.

Healthcare analysts point to a myriad of systemic barriers driving this low compliance. Patient factors such as lack of risk awareness, financial burdens, and transportation logistics play a significant role. Provider-side challenges, including fragmented healthcare infrastructure and inconsistent primary care follow-up, further widen the gap. Additionally, traditional ultrasound imaging can be limited by operator dependence and patient body habitus, sometimes resulting in suboptimal image quality that misses the smallest, most treatable tumors.

The human cost of this 9 percent compliance rate is severe. When liver cancer is detected at a localized, early stage, the five-year relative survival rate is approximately 37 percent, and for those eligible for resection or transplant, survival frequently reaches 60 to 70 percent. However, because the disease is largely asymptomatic in its early phases, most cases are diagnosed after the cancer has spread regionally or distantly, plummeting the five-year survival rate to just 13 percent and 3 percent, respectively.

Can Liquid Biopsy Revolutionize Surveillance?

To bridge this massive gap in preventative care, the diagnostics industry is aggressively pursuing "liquid biopsies"—non-invasive blood tests designed to detect cancer biomarkers before tumors become clinically apparent on traditional imaging.

Helio Genomics is positioning its lead product, HelioLiver, as a solution to the adherence crisis. The laboratory-developed test utilizes a proprietary AI algorithm to analyze cell-free DNA (cfDNA) methylation patterns, protein biomarkers, and demographic data from a simple blood draw. By removing the logistical friction of scheduling and attending imaging appointments, developers hope blood-based surveillance will dramatically increase the number of high-risk individuals who actually get screened.

"Liver cancer is too often silent until the window for curative treatment has closed," said Bharat Tewarie, MD, MBA, Chief Executive Officer of Helio Genomics. "This resolution can turn awareness into action—helping more people understand their risk, receive appropriate surveillance, and find cancer earlier. We are grateful to Representative Bacon and his office for leading this resolution, and proud to have worked with them to put early detection at the center of it. When it comes to liver cancer, every week matters."

The clinical foundation for these claims rests on trials like the prospective multicenter CLiMB study (NCT03694600), which compared the blood test's performance against traditional ultrasound. While liquid biopsies show immense promise, particularly in identifying early-stage lesions, integrating them into standard clinical practice remains a complex hurdle. Current guidelines from the American Association for the Study of Liver Diseases (AASLD) still recommend ultrasound as the primary surveillance tool. Hepatologists caution that while blood-based tests are highly anticipated, they require robust, peer-reviewed validation in large populations to prove they can serve as a standalone replacement rather than an adjunctive tool.

The Intersection of Advocacy and Commercial Strategy

The collaboration between Helio Genomics and Rep. Bacon's office underscores a strategic dynamic in the modern healthcare economy: the symbiotic relationship between legislative advocacy and medical technology commercialization.

Diagnostic startups frequently engage with public health initiatives and patient advocacy organizations, such as the American Liver Foundation, to amplify awareness of the diseases their products target. While these efforts undeniably serve the public good by educating at-risk populations, they simultaneously cultivate the market conditions necessary for new technologies to thrive. By establishing a National Liver Cancer Awareness Day, companies can leverage the resulting public discourse to lobby for broader insurance reimbursement, FDA clearances, and eventual inclusion in clinical guidelines.

"Public awareness campaigns increase screening rates in breast, colorectal, and cervical cancer. Liver cancer should not be the exception," Tewarie noted, drawing a direct parallel to the highly successful, multi-billion-dollar screening ecosystems established around other malignancies. "October 15 should be the day a clinician tells an at-risk patient the surveillance is overdue, and the day a family asks the question that is too often asked too late."

For lawmakers, partnering with industry innovators provides actionable solutions to the public health crises they are legislating against. Representative Bacon, previously recognized as an American Liver Foundation Congressional Champion, views the resolution as a necessary intervention.

"Liver cancer is taking too many lives because too many people do not know they are at risk until it is too late," said Representative Bacon. "Designating October 15 as Liver Cancer Awareness Day is a practical step toward helping patients and clinicians act sooner, when detection can lead to more treatment options. I am proud to lead this resolution and grateful to the patients, families, advocates, and companies working to make earlier detection a reality."

Navigating the Path to Clinical Adoption

As the resolution moves through the House Committee on Energy and Commerce, the broader liquid biopsy market continues its rapid expansion. Driven by advances in machine learning and next-generation sequencing, the sector is attracting significant venture capital and institutional investment.

However, the path from a laboratory-developed test to a universally adopted standard of care is fraught with regulatory and financial challenges. To truly disrupt the 9 percent screening trap, novel diagnostics must not only prove their clinical superiority but also secure broad payer coverage. Insurance companies and Medicare closely scrutinize the cost-effectiveness of new tests, demanding definitive proof that early detection translates to improved overall survival and reduced downstream treatment costs.

The push for October 15th as a day of national focus represents more than just a calendar designation; it is a calculated effort to align public awareness, legislative momentum, and private-sector innovation. If successful, this multi-front strategy could finally shift the paradigm for liver cancer from late-stage crisis management to proactive, life-saving intervention.